National Health (Originator Brand) Amendment Determination 2017 (No. 8) (PB 98 of 2017) (Cth)

PB 98 of 2017

National Health (Originator Brand) Amendment Determination 2017 (No. 8)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated    28 November 2017

______________________________________

LISA LA RANCE

Assistant Secretary

Pricing and Policy Branch

Technology Assessment and Access Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2017 (No. 8).

(2)     This Determination may also be cited as PB 98 of 2017.

1. Commencement

This Determination commences on 1 December 2017.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1 (after table item 71)

insert:

71A Dutasteride Avodart

[2]   Schedule 1 (after table item 107)

insert:

107A Hyoscine Buscopan